Genome & Company Amends Stock Option Grant: Lower Exercise Price and Increased Shares

Amendment: Change in stock option grant terms (amended on May 14, 2026)
Exercise price adjusted: KRW 20,210 → KRW 6,090 (reflecting capital increases per contract clause 5)
Granted shares increased: 8,000 → 10,000 common shares
Number of grantees decreased: 2 → 1 (due to resignation/forfeiture)
Total granted shares increased: 1,941,396 → 4,092,568 (including new grants and exercises)
Exercise period: Aug 23, 2024 ~ Aug 22, 2031
Fair value using binomial model; closing price before grant: KRW 20,300, exercise price KRW 6,090, volatility 52.98%